Jun 11, 2026 07:00AM
Jun 11, 2026 07:00AM
Jun 9, 2026 04:30PM
Jun 9, 2026 04:30PM
May 13, 2026 05:46AM
May 13, 2026 02:38AM
May 4, 2026 08:00AM Takeda reports positive Phase 2/3 trial results for TAK-881 in immune disorder
May 4, 2026 08:00AM
Mar 30, 2026 04:21AM
Mar 28, 2026 03:00PM
Mar 2, 2026 06:01AM
Mar 2, 2026 02:00AM
Feb 19, 2026 12:00PM
Feb 19, 2026 12:00PM Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
Feb 10, 2026 04:50AM
Feb 10, 2026 03:15AM
Jan 29, 2026 01:37AM
Jan 22, 2026 07:45AM
Jan 22, 2026 07:45AM
Jan 14, 2026 09:00AM
Jan 5, 2026 07:03AM Takeda and Protagonist submit drug application for polycythemia vera treatment
Jan 5, 2026 07:00AM
Dec 18, 2025 03:00AM
Dec 18, 2025 03:00AM
Dec 8, 2025 02:54AM
Dec 6, 2025 09:30AM
Nov 7, 2025 11:01AM
Nov 7, 2025 11:00AM Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
Nov 3, 2025 08:33AM
Nov 3, 2025 07:00AM
Oct 30, 2025 03:04AM
Oct 27, 2025 08:35AM
Oct 21, 2025 08:25PM
Oct 21, 2025 08:25PM
Sep 23, 2025 06:04PM 20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries
Sep 16, 2025 08:02AM
Sep 16, 2025 08:00AM
Sep 11, 2025 08:45AM
Sep 11, 2025 08:45AM
Sep 8, 2025 03:00AM
Sep 8, 2025 03:00AM
Sep 5, 2025 08:45PM FDA approves expanded VONVENDI use for von Willebrand disease patients
Sep 5, 2025 08:45PM
Jul 30, 2025 02:41AM
Jul 21, 2025 08:01AM
Jul 21, 2025 08:00AM
Jul 14, 2025 05:55AM
Jul 14, 2025 03:00AM
Jun 30, 2025 08:00AM Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹
Jun 25, 2025 03:07AM

1,157,649 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All